SNH6, a new dual-action therapy, has the potential to restore mitochondria function and may ultimately be used to treat cardiomyopathy in patients with Friedreich’s ataxia (FA), a mouse study found. The compound’s dual mechanism allows it to both reduce the buildup of iron and modulate levels of important mitochondrial […]
Click here to view original web page at friedreichsataxianews.com
